Anzeige
Mehr »
Login
Mittwoch, 19.02.2020 Börsentäglich über 12.000 News von 619 internationalen Medien
Nach 240 % Plus- Neue Empfehlung! Die Revolution der Gold und Cannabisbranche!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
14:42Pfizer's VYNDAQEL gets EC approval for treatment of ATTR-CM
10:42Merck receives complete response letter from FDA for sBLAs for KEYTRUDA six-week dosing schedule
09:42ALX Oncology's ALX148 receives two fast track designations from FDA
08:42Audentes Therapeutics to build gene therapy manufacturing facility in North Carolina
DiPharmaMar, Jazz get FDA priority review for lurbinectedin in relapsed SCLC
DiFDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the US
DiAscletis' IND filing for its NASH drug accepted by NMPA
DiNovartis gets EC nod for Beovu to treat wet AMD
MoOpdivo delivers superior five-year survival results in renal cell carcinoma
MoCelltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn's disease and ulcerative colitis
MoNew phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn's Disease achieved clinical remission after two doses of STELARA
MoEpizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma
FrSeattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer
FrThe US FDA accepts for priority review Bristol-Myers Squibb's BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma
FrRoche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC
DoALX Oncology announces closing of $105m Series C financing
DoDeciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours
DoMerck's Keytruda plus chemotherapy meets primary endpoint in mTNBC trial
12.02.Novartis' capmatinib gets FDA priority review in METex14 mutated advanced NSCLC
12.02.Dr. Reddy's Laboratories to acquire select business divisions of Wockhardt in India
12.02.Ligand agrees to acquire core assets, partnered programmes and ion channel technologies from Icagen
12.02.Pfizer, Astellas' Xtandi significantly improves OS in phase 3 prostate cancer study
11.02.Lilly's solanezumab fails to meet objective in phase 2/3 DIAN-TU Study
11.02.Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020
11.02.Biohaven's troriluzole study for generalised anxiety disorder misses primary endpoint